Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2010
This is a single-center, open-label, dose escalation study of patients with alpha-mannosidosis. 10 patients will be enrolled in this study receiving intravenous infusions of Lamazym. In order to avoid development of delayed hypersensitivity all patients will continue weekly treatment at the designated dose until the Safety Committee approves transfer to the rhLAMAN-03 protocol. It is the hypothesis that Lamazym is safe to use.
Epistemonikos ID: 64e4fe8c04aab9746bef9cbb9ea500efb330a95d
First added on: May 06, 2024